Balanced Intestinal Flora. Enhanced Well-Being.
It all starts in the gut! Gastrointestinal health remains the first reason why consumers buy probiotics today and it still represents the first area of clinical evidence for probiotics. With 150 publications, including preclinical and clinical studies, Lallemand Health Solutions has strongly documented its strains and formulas for gut health applications and well-being.
Our probiotic bacteria and yeast solutions, demonstrate beneficial effects on microbiota balance, occasional diarrhea, occasional constipation, and support specific populations such as babies during their first year of life as well as adults with serious gut conditions.
Amongst them, probiotic formula Lacidofil® cumulates 26 clinical studies in gut health in kids, adults and pregnant women specifically. B. lactis Lafti® B94 is a single strain selected among 40 Bifidobacteria species, for its good synergy with prebiotics. It has been documented in infant and children for gut comfort. Probiotic yeast S. boulardii, also available as an organic ingredient, is the most documented probiotic in the world, studied in over 100 clinical studies in both kids and adults. IBacilluS+ is a highly documented combination of robust bacterial strains, with over 120 clinical trials in adults with serious gut conditions to demonstrate minimizing recurrent symptoms and maximizing quality of life.
Latest news
Lacidofil®:
- A new study highlights the potential of Lacidofil® as an adjuvant to standard therapy as an effective approach for Helicobacter pylori eradication.
B. lactis Lafti® B94:
- A new comprehensive review reaffirmed the significant benefits of the probiotic bacterial strain B. lactis Lafti® B94, whether used alone or as a synbiotic, for promoting gut health in infants and children. The review emphasizes on the strain’s robust safety profile and the wealth of scientific data supporting its use for children’s optimal development.
S. boulardii:
- We have launched in exclusivity, the first and unique organic version of probiotic yeast Saccharomyces boulardii. This innovative positioning for S. boulardii creates new opportunities for consumers looking to make conscious buying choices.
IBacilluS+:
- A new review has been published demonstrating the potential of IBacilluS+, a combination of Bacillus subtilis R0179 and Enterococcus faecium R0026; as an effective adjuvant to conventional irritable bowel syndrome (IBS) therapies.
L. paracasei HA-196:
Probiotic strain L. paracasei HA-196 has gained new indication for from Health Canada recognizing its beneficial effects to help support healthy bowel habits in adults with irritable bowel symptoms, at a daily dose 10B CFU.
Best probiotic strains and formulas
More news
Gut health represents the first area of clinical evidence
for probiotics, and the role of probiotics to support a healthy and balanced gut microflora is well
documented. When looking at the probiotic products on the market, nearly two-thirds are positioned
to support gut health and promote digestion; research in this area is still very active and shows no
signs of slowing down. Read more